Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2001 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Showing results for
aderem plus
Your search for
adorem-plus
retrieved no results
Co-Targeting MAP Kinase and Pi3K-Akt-mTOR Pathways in Meningioma: Preclinical Study of Alpelisib and Trametinib.
Cancers (Basel). 2022 Sep 13;14(18):4448. doi: 10.3390/cancers14184448.
Cancers (Basel). 2022.
PMID: 36139608
Free PMC article.
Trametinib also strongly inhibited cell proliferation and induced AKT activation. Combined treatment with alpelisib plus trametinib reversed the AKT activation induced by trametinib and induced an additive inhibitory effect irrespective of the cell lines or tumor features. …
Trametinib also strongly inhibited cell proliferation and induced AKT activation. Combined treatment with alpelisib plus trametinib r …
Macrophages exposed continuously to lipopolysaccharide and other agonists that act via toll-like receptors exhibit a sustained and additive activation state.
Hume DA, Underhill DM, Sweet MJ, Ozinsky AO, Liew FY, Aderem A.
Hume DA, et al.
BMC Immunol. 2001;2:11. doi: 10.1186/1471-2172-2-11. Epub 2001 Oct 12.
BMC Immunol. 2001.
PMID: 11686851
Free PMC article.
Transient expression of constitutively active forms of TLR4 or TLR2 plus TLR6 stimulated IL-12 promoter activity. The effect of LPS, a TLR4 agonist, was additive with that of TLR2/6 but not TLR4, whilst that of lipopeptide, a TLR2 agonist, was additive with TLR4 but not TL …
Transient expression of constitutively active forms of TLR4 or TLR2 plus TLR6 stimulated IL-12 promoter activity. The effect of LPS, …
Item in Clipboard
Cite
Cite